30 related articles for article (PubMed ID: 29717448)
1. The sympathomimetic agonist mirabegron did not lower
Drexler B; Passweg JR; Tzankov A; Bigler M; Theocharides AP; Cantoni N; Keller P; Stussi G; Ruefer A; Benz R; Favre G; Lundberg P; Nienhold R; Fuhrer A; Biaggi C; Manz MG; Bargetzi M; Mendez-Ferrer S; Skoda RC;
Haematologica; 2019 Apr; 104(4):710-716. PubMed ID: 30409796
[TBL] [Abstract][Full Text] [Related]
2. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.
Nielsen C; Birgens HS; Nordestgaard BG; Kjaer L; Bojesen SE
Haematologica; 2011 Mar; 96(3):450-3. PubMed ID: 21160067
[TBL] [Abstract][Full Text] [Related]
3. Systematic analysis of copper, zinc, and selenium levels in JAK2 V617F-positive myeloproliferative neoplasms.
Shivarov V; Tsvetkova G; Atanasova B; Genova MP; Ivanova I; Hadjiev E; Ivanova M
Ann Hematol; 2024 Jun; 103(6):2177-2179. PubMed ID: 38233569
[No Abstract] [Full Text] [Related]
4. PCM1::JAK2 myeloproliferative neoplasm suggested by bone marrow histopathological features.
Loscocco GG; Santi R
Blood; 2024 Jun; 143(23):2439. PubMed ID: 38842862
[No Abstract] [Full Text] [Related]
5. Serum Has Higher Proportion of Janus Kinase 2 V617F Mutation Compared to Paired EDTA-Whole Blood Sample: A Model for Somatic Mutation Quantification Using qPCR and the 2
Barra GB; Santa Rita TH; Almeida ALSC; Jácomo RH; Nery LFA
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32178286
[TBL] [Abstract][Full Text] [Related]
6. Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2
Liu Y; Han C; Li J; Xu S; Xiao Z; Guo Z; Rao S; Yao Y
Glob Med Genet; 2024 Jun; 11(2):132-141. PubMed ID: 38585044
[TBL] [Abstract][Full Text] [Related]
7. Digital PCR and the QuantStudio™ 3D Digital PCR System.
Laig M; Fekete C; Majumdar N
Methods Mol Biol; 2020; 2065():209-231. PubMed ID: 31578698
[TBL] [Abstract][Full Text] [Related]
8. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN).
Stegelmann F; Teichmann LL; Heidel FH; Crodel CC; Ernst T; Kreil S; Reiter A; Otten S; Schauer S; Körber RM; Kricheldorf K; Isfort S; Döhner H; Brümmendorf TH; Griesshammer M; Döhner K; Koschmieder S
Leukemia; 2023 Apr; 37(4):924-928. PubMed ID: 36828867
[No Abstract] [Full Text] [Related]
9. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
10. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of JAK2 V617F Allele Burden by Using the QuantStudio™ 3D Digital PCR System.
Kinz E; Muendlein A
Methods Mol Biol; 2018; 1768():257-273. PubMed ID: 29717448
[TBL] [Abstract][Full Text] [Related]
12. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
14. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
15. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
